Palisade Bio Inc Overview
Industry: Biotechnology
Sector: Healthcare
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.
Palisade Bio Inc is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.
Score
Price History & Performance
Review Palisade Bio Inc in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.
Recent News
Palisade Bio Inc Competitors
Palisade Bio Inc operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.
Earnings Per Share
EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.
Continue the analysis
Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.
View plans